Time to reconsider CD33 single nucleotide polymorphism in the response to gemtuzumab ozogamicin

Jatinder K. Lamba, Soheil Meshinchi

Open source

DOI: 10.3324/haematol.2021.279043
Published: 2021-05-27
Container: Haematologica
Publisher: Ferrata Storti Foundation (Haematologica)
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.3324/haematol.2021.279043,
  title = {Time to reconsider CD33 single nucleotide polymorphism in the response to gemtuzumab ozogamicin},
  author = {Jatinder K. Lamba and Soheil Meshinchi},
  year = {2021},
  journal = {Haematologica},
  doi = {10.3324/haematol.2021.279043},
  url = {https://doi.org/10.3324/haematol.2021.279043}
}

RIS

TY  - JOUR
TI  - Time to reconsider CD33 single nucleotide polymorphism in the response to gemtuzumab ozogamicin
AU  - Jatinder K. Lamba
AU  - Soheil Meshinchi
PY  - 2021
JO  - Haematologica
DO  - 10.3324/haematol.2021.279043
UR  - https://doi.org/10.3324/haematol.2021.279043
ER  -

APA

Lamba, J. K., & Meshinchi, S. (2021). Time to reconsider CD33 single nucleotide polymorphism in the response to gemtuzumab ozogamicin. Haematologica. https://doi.org/10.3324/haematol.2021.279043

Source records

crossref · retrieved 2026-09-26T18:03:44.769Z